drugset / Trial / NCT05431725
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of Influenza vaccine (Split virion), Inactivated, Quadrivalent developed by Sinovac Biotech Co., Ltd. (Sinovac-QIV) as compared to a licensed comparator in Chile and Philippines, Vaxigrip Tetra™ (Vaxigrip Tetra-QIV) in individuals aged 3 years and older.
Timeline
- Start
- 2022-07-18
- Primary completion
- 2023-07-19
- Completion
- 2023-07-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Control Quadrivalent influenza virus vaccine | Vaccine | 15 ug | Intramuscular |
| Comparator | Control Quadrivalent influenza virus vaccine | Vaccine | 0.5 ml | Intramuscular |
| Subject | Influenza Vaccine (Split Virion), Inactivated, Quadrivalent | Vaccine | 15 ug | Intramuscular |
| Subject | Influenza Vaccine (Split Virion), Inactivated, Quadrivalent | Vaccine | 0.5 ml | Intramuscular |